Overview

• ABIVAX will deliver late-breaking eight-week induction results from the Phase 3 ABTECT trials at the UEG Congress in Berlin on October 6.
• The dataset will report outcomes for patients who previously did not respond to advanced therapies, a key test for real-world utility.
• The company will host an investor call and a scientific symposium on ulcerative colitis treatment mechanisms alongside the meeting.
• In July, topline induction data showed a pooled clinical remission benefit of 16.4 percentage points versus placebo, with the 50 mg dose achieving a 19.3% placebo-adjusted remission rate.
• Maintenance studies continue to support planned U.S. and EU submissions in the second half of 2026, backed by a $650 million July offering that extends cash runway into Q4 2027.